Skip to main content
Journal cover image

Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.

Publication ,  Journal Article
Januzzi, JL; Ahmad, T; Mulder, H; Coles, A; Anstrom, KJ; Adams, KF; Ezekowitz, JA; Fiuzat, M; Houston-Miller, N; Mark, DB; Piña, IL ...
Published in: J Am Coll Cardiol
September 3, 2019

BACKGROUND: The GUIDE-IT (GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) trial demonstrated that a strategy to "guide" application of guideline-directed medical therapy (GDMT) by reducing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) was not superior to GDMT alone. OBJECTIVES: The purpose of this study was to examine the prognostic meaning of NT-proBNP changes following heart failure (HF) therapy intensification relative to the goal NT-proBNP value of 1,000 pg/ml explored in the GUIDE-IT trial. METHODS: A total of 638 study participants were included who were alive and had available NT-proBNP results 90 days after randomization. Rates of subsequent cardiovascular (CV) death/HF hospitalization or all-cause mortality during follow-up and Kansas City Cardiomyopathy Questionnaire (KCCQ) overall scores were analyzed. RESULTS: A total of 198 (31.0%) subjects had an NT-proBNP ≤1,000 pg/ml at 90 days with no difference in achievement of NT-proBNP goal between the biomarker-guided and usual care arms. NT-proBNP ≤1,000 pg/ml by 90 days was associated with longer freedom from CV/HF hospitalization or all-cause mortality (p < 0.001 for both) and lower adjusted hazard of subsequent HF hospitalization/CV death (hazard ratio: 0.26; 95% confidence interval: 0.15 to 0.46; p < 0.001) and all-cause mortality (hazard ratio: 0.34; 95% confidence interval: 0.15 to 0.77; p = 0.009). Regardless of elevated baseline concentration, an NT-proBNP ≤1,000 pg/ml at 90 days was associated with better outcomes and significantly better KCCQ overall scores (p = 0.02). CONCLUSIONS: Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to ≤1,000 pg/ml during GDMT had better outcomes. These findings may help to understand the results of the GUIDE-IT trial. (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment [GUIDE-IT]; NCT01685840).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

September 3, 2019

Volume

74

Issue

9

Start / End Page

1205 / 1217

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Stroke Volume
  • Prognosis
  • Practice Guidelines as Topic
  • Peptide Fragments
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Male
  • Humans
  • Heart Failure
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Januzzi, J. L., Ahmad, T., Mulder, H., Coles, A., Anstrom, K. J., Adams, K. F., … O’Connor, C. M. (2019). Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol, 74(9), 1205–1217. https://doi.org/10.1016/j.jacc.2019.06.055
Januzzi, James L., Tariq Ahmad, Hillary Mulder, Adrian Coles, Kevin J. Anstrom, Kirkwood F. Adams, Justin A. Ezekowitz, et al. “Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.J Am Coll Cardiol 74, no. 9 (September 3, 2019): 1205–17. https://doi.org/10.1016/j.jacc.2019.06.055.
Januzzi JL, Ahmad T, Mulder H, Coles A, Anstrom KJ, Adams KF, et al. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 Sep 3;74(9):1205–17.
Januzzi, James L., et al. “Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.J Am Coll Cardiol, vol. 74, no. 9, Sept. 2019, pp. 1205–17. Pubmed, doi:10.1016/j.jacc.2019.06.055.
Januzzi JL, Ahmad T, Mulder H, Coles A, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Mark DB, Piña IL, Passmore G, Whellan DJ, Cooper LS, Leifer ES, Desvigne-Nickens P, Felker GM, O’Connor CM. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 Sep 3;74(9):1205–1217.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

September 3, 2019

Volume

74

Issue

9

Start / End Page

1205 / 1217

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Stroke Volume
  • Prognosis
  • Practice Guidelines as Topic
  • Peptide Fragments
  • Natriuretic Peptide, Brain
  • Middle Aged
  • Male
  • Humans
  • Heart Failure